Intermediate Endpoint Proposals For Cancer Immunotherapies Don’t Sway FDA
Executive Summary
An issue brief laying out four potential intermediate endpoints for checkpoint modulators draws a cautious response from FDA representatives at a cancer research conference. The endpoints may prove useful for exploratory purposes but are far from ready to serve as the basis for registration, agency says.